Browse our anti-IL3RA (IL3RA) Antibodies

Human Interleukin 3 Receptor, alpha (Low Affinity) (IL3RA) interaction partners

1. CD123 expression may thus be useful for assessing AML patients' prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.

2. High IL3RA expression is associated with breast cancer.

3. Family-based whole genome analysis of a family with hereditary pulmonary alveolar proteinosis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings.

4. Our data define the mechanisms by which SL-101 targets acute myeloid leukemia (AML)and warrant further investigation of the clinical application of SL-101 and other CD123-targeting strategies in AML.

5. Data show that the N-terminal domain (NTD) of interleukin 3 receptor subunit alpha (IL3Ralpha) exhibits exquisite flexibility and a dynamic transition from a high to a low mobility state upon cytokine binding.

6. the oncogenic events of FLT3/ITD happen at a cell stage possessing CD123

7. IL-3 hardly down-regulates the alpha-chain of its receptor without depleting the common beta-chain, which enables extraordinarily sustained signaling events, predominantly the activation of Stat5.

8. Data indicate that CD123 was preferentially expressed among CD33/CD117-positive precursor-T-acute lymphoblastic leukemia (T-ALL).

9. CD123 positivity represents a marker that can facilitate identification of the early T-cell precursor leukemia subtype, but the lack of sensitivity by immunohistochemistry limits the diagnostic utility.

10. CD123 expression is associated with systemic mastocytosis.

11. Our results suggest that the CD34/CD25/CD123/CD99(+) LAIP is strictly associated with FLT3-ITD-positive cells.

12. Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset.

13. CD96 and CD123 are expressed in bone marrow cells of patients with myelodysplastic syndromes

14. High interleukin-3 receptor alpha is associated with blastic plasmacytoid dendritic cell neoplasm.

15. High CD123 expression is associated with systemic mastocytosis.

16. CD123+ plasmacytoid dendritic cells contribute to the sarcoidal granulomas associated with injected permanent fillers.

17. 87.8% of AMLs express CD33. Additionally, 9.4% of AMLs express CD123 without concomitant CD33 expression.

18. Increases in CD34(+)CD38(-)CD123(+) cells may reflect malignant clonal cells with aberrant differentiation, overproliferation, and decreased apoptosis in myelodysplastic syndrome, which were similar to acute myeloid leukemia.

19. In the present study we analyzed the expression of four cell surface antigens relevant to human hematopoiesis-CD90, CD96, CD117, and CD123-in bone marrow from pediatric acute myeloid leukemia patients and normal control subjects.

20. We conclude the hMICL/CD123-based MFC assay is a promising MRD tool in AML.

Mouse (Murine) Interleukin 3 Receptor, alpha (Low Affinity) (IL3RA) interaction partners

1. High IL3RA expression is associated with breast cancer.

2. expression of the interleukin 3 receptor alpha (Il3ra also known as Cd123) subunit is dependent on Jmjd2/Kdm4 through a mechanism involving removal of H3K9me3 from the promoter of the Il3ra gene.

3. Data indicate that the proliferative and differentiative effect of saponins from Sanguisorba officinalis (DYS) on megakaryocyte progenitor cells is correlated to the up-regulation of IL-3 receptor and c-kit expression.

4. Findings indicate that SLP-76 is an essential signaling component for basophil activation downstream of both FcepsilonRI and the IL-3 receptor.

5. Interleukin-3/dendritic cells expressed higher levels of interleukin-3 receptor.